More management changes at Adaptimmune

2 August 2019
adaptimmune-big

A month after announcing that Adrian Rawcliffe is to succeed the retiring James Noble as chief executive in September, Adaptimmune (Nasdaq:ADAP) has revealed further management changes.

John Lunger, previously senior vice president for manufacturing and supply chain, has been promoted to chief patient supply officer as the Anglo-American biopharma gears up for commercial delivery of products.

Meanwhile, Rafael Amado, president of R&D, will this month leave the company, which calls itself a leader in T-cell therapy to treat cancer, and the firm is seeking both a chief medical officer and a chief financial officer, the latter being Mr Rawcliffe’s former role.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology